Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

464.56 -2.51 (-0.54%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
54 55 Next >
Rocket Pharmaceuticals Stock Sees RS Rating Pops Higher
A Relative Strength Rating upgrade for Rocket Pharmaceuticals shows improving technical performance. Will it continue? 
Via Investor's Business Daily
Questions Surround Vertex/CRISPR's Sickle Cell Gene Therapy As FDA AdComm Meeting Approaches
The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee will meet next  
Via Benzinga
Exposures Product Safety
Got $1,000? 3 Growth Stocks to Buy That Could Double Your Money
These companies come from very different industries, but each has businesses that investors may find compelling. 
Via The Motley Fool
2 Healthcare Stocks That Could Make You Richer
The need for healthcare is consistent and ongoing, a reality that makes this industry resilient to economic downturns. 
Via The Motley Fool
2 Top Healthcare Stocks Defying the Bear Market
These companies are building out their revenue and profit streams, and the proof is in the pudding. 
Via The Motley Fool
This Market-Beating Growth Stock Is Set to Outperform Yet Again in 2024
This rare disease company is on a roll. 
Via The Motley Fool
A Look Into Vertex Pharmaceuticals Inc's Price Over Earnings
Via Benzinga
The Latest Analyst Ratings for Vertex Pharmaceuticals
Via Benzinga
IBD's 100 Best ESG Companies For 2023
The companies on our list combine high sustainability scores and top stock ratings. 
Via Investor's Business Daily
2 Best Healthcare Stocks to Buy Right Now
The healthcare industry is an explosive space full of promising, profitable companies. 
Via The Motley Fool
Vertex to Present at Upcoming Investor Conferences
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Pharmaceuticals: Buy at the High?
Vertex shares have been flying high in recent times. 
Via The Motley Fool
3 Healthcare Stocks to Buy and Hold for the Next 10 Years
Great healthcare businesses are out there and their stocks are ripe for the picking. 
Via The Motley Fool
2 No-Brainer Growth Stocks to Buy Right Now
These businesses are thriving and raking in profits. 
Via The Motley Fool
2 Fantastic Growth Stocks to Buy Hand Over Fist
These stocks make great bargains today. 
Via The Motley Fool
3 Red-Hot Growth Stocks That Are Still Cheap Buys
It's not too late to invest in these great businesses. 
Via The Motley Fool
Apellis Pharmaceuticals Stock Shows Rising Relative Strength
A Relative Strength Rating upgrade for Apellis Pharmaceuticals shows improving technical performance. Will it continue? 
Via Investor's Business Daily
The Best Stocks to Invest $5,000 In Right Now
Today, the following three healthcare players look like fantastic bargains. 
Via The Motley Fool
3 Unstoppable Stocks to Buy Sooner Rather Than Later
Now is the time to invest in these great stocks. 
Via The Motley Fool
3 Monster Stocks to Buy Without Any Hesitation
These big stocks could become a lot bigger. 
Via The Motley Fool
4 Ways to Grow $100,000 Into $1 Million for Retirement
Investing for big-time growth doesn't have to be risky. 
Via The Motley Fool
Vertex Pharmaceuticals, Gilead Sciences And 2 Other Stocks Insiders Are Selling
The Nasdaq 100 closed lower by over 200 points on Wednesday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
3 Gene Editing Stocks to Generate Super-Charged Gains
As things progress, such techniques may be able to knock out every disease known, creating massive opportunity for gene-editing stocks. 
Via InvestorPlace
Intellia Stumbles As It Aims For A First-Ever In CRISPR Gene Editing
The company can begin a pivotal study of its treatment for cardiomyopathy. 
Via Investor's Business Daily
The Stock Market Is Resilient But How Long Will It Last? Your Mid-October Update
We're continuing to see resilience in the US Stock Market in the headwinds of otherwise bearish or bad news, but is this the beginning of a larger rally or may the resiliency come to an end soon? 
Via Talk Markets
Mixed Signals For CRISPR Therapeutics, Analyst Weighs Barriers, Potential Sales For Sickle Cell Therapy
Cantor Fitzgerald has downgraded CRISPR Therapeutics AG (NASDAQ: CRSP) to Neutral from Ov 
Via Benzinga
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) Sets New 52-Week High in Tuesday Session
Via Investor Brand Network
Healthcare Portfolio Focus Stocks
The macro news has been a steady headwind with rising rates offering 5% risk-free treasury yields. 
Via Talk Markets
Revolution Medicines Stock Joins Elite Club With RS Ratings Over 90
Revolution Medicines shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
2 Healthcare Stocks Near 52-Week Highs Still Worth Buying
These two large-cap biopharma companies could have more room to run. 
Via The Motley Fool
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
54 55 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.